Evidence check: ApoB in the context of Langlebigkeit

ApoB (apolipoprotein B) is a core component of atherogenic lipoproteins (LDL, VLDL) and is considered a stronger predictor of cardiovascular risk than LDL cholesterol alone. In longevity research, ApoB is indirectly relevant: elevated levels promote atherosclerosis, reduce healthy lifespan, and are associated with increased mortality. However, ApoB is not a direct longevity marker but a risk factor that must be interpreted in the context of diet, exercise, and genetics. Direct-to-consumer tests often measure LDL-C rather than ApoB. The evidence for ApoB as a surrogate endpoint is strong (human-observational, Mendelian randomization), but measuring it alone without other lipid parameters and lifestyle factors is insufficient for longevity assessment. Caveat: No randomized trials have shown that lowering ApoB directly extends lifespan; the benefit comes from reducing cardiovascular events.